insights_auto
Prečo akcie ALMKT klesli 3,38%?
Preskúmať podrobnejšiechevron_right
ALMKT:EPA
Mauna Kea Technologies SA
0,12 €
arrow_downward
-3,38%(-0,0042) 1 d.
5. 10., 17:35:04 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre ALMKT…
Otvoriť
0,13 €
Vysoká
0,13 €
Nízka
0,12 €
Trh. kap.
24,25 mil.
Priem. obj.
440,14 tis.
Objem
560,78 tis.
Pomer cena/zárobky
0,98
Max. za 52 týž.
0,23 €
Min. za 52 týž.
0,07 €
Výnosy na akciu
0,12 €
Akcie v obehu
195,26 mil.
Počet zamestnancov
59
Otvoriť
0,13 €
Vysoká
0,13 €
Nízka
0,12 €
Trh. kap.
24,25 mil.
Priem. obj.
440,14 tis.
Objem
560,78 tis.
Pomer cena/zárobky
0,98
Max. za 52 týž.
0,23 €
Min. za 52 týž.
0,07 €
Výnosy na akciu
0,12 €
Akcie v obehu
195,26 mil.
Počet zamestnancov
59
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
sUAS News
·
pred 23 minútami
Powerus (Nasdaq: PUSA) Awarded $82 Million Order for Counter-Unmanned Aerial Systems
Eagle-Tribune
·
pred 27 minútami
US stocks are rising near their records, with the Nasdaq composite on track for an all-time high
www.marketscreener.com
·
pred 19 minútami
SCWorx Corp. Announces Nasdaq Hearings Panel Grants Request for Reconsideration and Approves Continued Listing on The Nasdaq Capital Market
Seeking Alpha
·
pred 1 hodinou
S&P 500 nears record high despite the struggling underlining breadth
Profil
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Informácie o subjekte Mauna Kea Technologies SA
Generálny riaditeľSacha Loiseau
Zamestnanci59
Dátum založenia2000
Hlavné sídlo-
Odvetvie-